MA, BM BCh, FRCP, DPhil, Executive Vice President and President of Global Research and Early Development, Celgene
Rupert Vessey graduated from Oxford University with degrees in Physiological Sciences (MA, First Class Honors) and Clinical Medicine (BM, BCh, proxime accessit). He subsequently undertook clinical training at several notable institutions in the UK. Rupert undertook basic research training in the laboratory of Professor Sir Stephen Bloom at the Hammersmith Hospital and under the direction of Professor Sir John Bell at the Institute for Molecular Medicine, Oxford where he completed a DPhil (PhD) in Molecular Immunology. In 2012 he was elected a Fellow of the Royal College of Physicians, London.
Rupert joined the pharmaceutical industry in 1997 and has worked for two major pharmaceutical companies in the UK and USA. At Glaxo he worked primarily in drug discovery, experimental medicine and early clinical development gaining experience in a wide range of respiratory and immunology projects including monoclonal antibodies, DNA vaccines, anti-inflammatory drugs and inhaled medicines for asthma and COPD. During 10 years at Merck Research Laboratories (MRL) Rupert benefitted from diverse experiences including a period working on the clinical development of varicella vaccines where he contributed to both the refrigerator stable formulation of VARIVAXÔ and the shingles vaccine, ZOSTAVAXÔ. Since 2006 Rupert held multiple roles in senior management including Vice President Molecular Profiling and Research Informatics and Site Head for Rosetta Inpharmatics, Seattle, Vice President Drug Discovery and Site Head for MRL Boston and Vice President Drug Discovery and Site Head for MRL Kenilworth. In 2011 Rupert was promoted to the position of Senior Vice President and Head of the MRL Respiratory and Immunology Franchise. Most recently Rupert was Senior Vice President and Head of Early Development and Discovery Sciences.
Commencing in February 2015 Rupert joined Celgene as Senior Vice President of Translational Development and Head of the Immunology and Inflammation Thematic Center of Excellence and in January 2016 assumed the role of Executive Vice President and President of Global Research and Early Development.